The FDA has approved the first oral medication for obesity, developed by Novo Nordisk, the company known for Wegovy. This is a significant step in making treatments more accessible for those struggling with obesity.
The new pill will hit pharmacies and telehealth providers in early 2026, starting at a monthly cost of $149 for the initial 1.5 mg dose. Details on higher doses and patient support options will be shared soon.
Following the news, Novo Nordisk’s stock rose about 10%. This approval positions them ahead of Eli Lilly, their main competitor, who is also working on an obesity pill. The market for GLP-1 drugs is booming, and analysts estimate it could be worth around $100 billion by the 2030s.
Dave Moore, a top executive at Novo Nordisk, shared insights about this development, noting that an oral option could encourage more people to seek treatment. “We’ve learned through research that having an oral option really motivates different segments,” he stated.
This pill not only aims to assist with weight loss but also helps reduce the risk of major cardiovascular events like heart attacks and strokes in obese adults with existing heart conditions.
The approval is backed by a phase three trial involving over 300 adults without diabetes. Results showed participants lost an average of 16.6% of their weight after 64 weeks on the 25 mg dose, though the weight loss was 13.6% when considering all patients.
Historically, obesity treatments have been mainly injectable, which can discourage some patients. The introduction of a pill could lead to new conversations between patients and doctors about treatment options.
As the demand for effective weight loss solutions grows, this innovation might change the landscape of obesity treatment significantly. With healthcare focusing more on prevention and management, the introduction of an oral option could lead to broader acceptance and usage among those seeking help.
For more on this topic, head to Reuters for comprehensive coverage and updates.
Source link
Business,Biotech and Pharmaceuticals,Eli Lilly and Co,Breaking News: Business,Health care industry,United States,Novo Nordisk A/S (B Shares) ADRhedged,business news
